Montelukast Sodium Market Size 2024-2028
The montelukast sodium market size is forecast to increase by USD 1.34 billion at a CAGR of 4.5% between 2023 and 2028.
- The market is experiencing significant growth due to the increasing demand for asthma medications. Asthma is a chronic respiratory condition affecting millions of people in North America, and the need for effective and convenient treatments, including incubators, inhalators, respirators, resuscitators, and other breathing devices, is on the rise. Furthermore, patient assistance initiatives by governments and advocacy groups are contributing to the market's expansion.
- However, challenges remain in the screening and diagnosis of asthma, which can hinder the accurate identification and treatment of patients. Despite these hurdles, the market is expected to continue its growth trajectory, driven by the unmet medical need for effective asthma treatments such as respiratory drugs and the ongoing efforts to improve diagnosis and patient care.
What will be the Montelukast Sodium Market Size During the Forecast Period?
- The market caters to the growing demand for effective treatments against noncommunicable diseases (NCDs), particularly chronic respiratory conditions such as asthma. Asthma affects millions worldwide, with a significant pediatric population relying on Montelukast sodium, available in dosage forms like tablets and oral solutions. Montelukast sodium, a leukotriene inhibitor, offers relief from various asthma triggers, including allergic rhinitis, urticaria, exercise-induced asthma, and bronchospasm.
- Beyond asthma, Montelukast sodium finds application in managing other chronic conditions, such as allergic coryza, fungal infections, pneumonia, COPD, and emphysema. Its utility extends to treating respiratory maladies exacerbated by environmental factors like pollution. The market's growth is driven by the increasing prevalence of chronic conditions and the need for effective, convenient treatment options. Pipeline analysis indicates ongoing research into Montelukast sodium's potential for treating additional indications, further expanding its reach. Montelukast sodium's versatility and efficacy make it a valuable tool in managing a range of respiratory conditions.
How is this Montelukast Sodium Industry segmented and which is the largest segment?
The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
- Type
- Tablets
- Chewable tablets
- Oral solutions
- Geography
- North America
- Canada
- US
- Europe
- Germany
- UK
- Asia
- China
- Rest of World (ROW)
- North America
By Type Insights
- The tablets segment is estimated to witness significant growth during the forecast period. Montelukast sodium, a leukotriene receptor antagonist, is available in two dosage forms: tablets and oral solutions. These medications are primarily used for the treatment of asthma, allergic rhinitis, and other chronic respiratory diseases in both children and adults. Montelukast sodium tablets are available in various shapes and sizes, including round, oblong, and caplet forms. Caplets are oblong tablets designed for easier swallowing. Some tablets have a unique coating that prevents them from dissolving in the stomach until they reach the intestines, ensuring optimal absorption. Montelukast sodium is also used to treat conditions like urticaria, exercise-induced asthma, and bronchospasm. Noncommunicable diseases, including chronic respiratory conditions, affect a significant portion of the pediatric population and the adult population worldwide.
- Factors like air pollution, smoking, and lifestyle choices contribute to the prevalence of these chronic conditions. Montelukast sodium, marketed under various brand names such as Singulair, is an essential medication for managing these conditions. Healthcare facilities and healthcare providers rely on these medications to provide effective treatment for their patients. Clinical trials and ongoing research continue to explore new uses for Montelukast sodium, including its potential application in treating fungal infections and respiratory maladies like pneumonia, emphysema, and allergic coryza. Montelukast sodium is available in various forms, including simple pills, chewable pills, powders, and liquid solutions, catering to diverse patient needs. Patients must adhere to the recommended dosage and consult their healthcare providers regarding potential adverse effects, such as gastrointestinal discomfort and respiratory dysfunction.
Get a glance at the Montelukast Sodium Industry report of share of various segments. Request Free Sample
The Tablets segment was valued at USD 2.26 billion in 2018 and showed a gradual increase during the forecast period.
Regional Analysis
- North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions, Request Free Sample
The market in North America is anticipated to dominate due to the high prevalence of asthma and other chronic respiratory diseases, a large patient population, and advanced healthcare infrastructure. The US, in particular, holds a significant market share due to favorable healthcare legislation and increasing disposable income. According to the Centers for Disease Control and Prevention (CDC), asthma affected approximately 25.7 million Americans or 7.8% of the population in 2019. The growing patient pool, coupled with ongoing research collaborations, is expected to fuel market growth. Montelukast Sodium, a leukotriene inhibitor, is used in the treatment of asthma, allergic rhinitis, and other chronic respiratory diseases.
Furthermore, it is available in various dosage forms, including tablets and oral solutions. Other indications include urticaria, exercise-induced asthma, and allergic coryza. Factors such as air pollution, smoking, and lifestyle changes contribute to the increasing prevalence of these conditions. The geriatric population is also at risk due to health complications from these diseases. Healthcare facilities and retail pharmacies are major distribution channels for Montelukast Sodium. Adverse effects include gastrointestinal discomfort and respiratory dysfunction.
Market Dynamics
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
What are the key market drivers leading to the rise in the adoption of Montelukast Sodium Industry?
- Increasing demand for asthma medications is the key driver of the market. Montelukast sodium is a crucial medication used in the treatment of asthma and other chronic respiratory diseases, including allergic rhinitis and urticaria, in both adults and children. Asthma, a noncommunicable disorder, affects over 25 million Americans, according to the Centers for Disease Control and Prevention (CDC). Montelukast sodium, available in dosage forms such as tablets and oral solutions, functions as a leukotriene inhibitor, counteracting the effects of leukotriene, a chemical released during inflammation that narrows airways and worsens breathing. The prevalence of asthma and other chronic respiratory diseases is on the rise due to various factors, including air pollution, smoking, and lifestyle changes.
- In the US, one in ten children, approximately 6.3 million, have been diagnosed with asthma, according to the Environmental Protection Agency (EPA). Montelukast sodium is often prescribed as a supplementary treatment to inhaled corticosteroids (ICS) to manage symptoms such as bronchospasm, wheezing, chest tightness, and coughing. Montelukast sodium is also used to treat other respiratory maladies, including exercise-induced asthma, allergic coryza, and pneumonia, in various pediatric and geriatric populations. Adverse effects of montelukast sodium include gastrointestinal discomfort and respiratory dysfunction. Healthcare facilities play a significant role in the diagnosis and treatment of asthma and other chronic respiratory diseases, and healthcare providers rely on clinical trials and pipeline analysis to stay informed about the latest treatments and developments.
What are the market trends shaping the Montelukast Sodium Industry?
- Patient assistance initiatives by governments and advocacy groups is the upcoming market trend. Montelukast sodium, a leukotriene inhibitor, is a vital medication used in the treatment of various chronic conditions, including asthma and allergic rhinitis. Noncommunicable diseases (NCDs), such as asthma and respiratory diseases, are a significant health concern for the pediatric population and the geriatric population alike. Montelukast sodium is available in dosage forms like tablets and oral solutions, making it convenient for patients to consume. Asthma, a chronic respiratory disease, affects millions of Americans, leading to symptoms like bronchospasm, allergic coryza, and exercise-induced asthma. Montelukast sodium plays a crucial role in managing asthma symptoms by inhibiting the effects of leukotriene, a chemical released during an allergic response.
- Allergic rhinitis, another condition treated with Montelukast sodium, is characterized by symptoms like nasal congestion, sneezing, and itching. Montelukast sodium's effectiveness in treating allergic rhinitis is well-established, making it a popular choice among healthcare providers. However, Montelukast sodium's use is not limited to allergic conditions. It is also used In the treatment of other respiratory diseases, such as pneumonia, emphysema, and fungal infections. Air pollution, smoking, and lifestyle changes are significant contributors to respiratory diseases, making Montelukast sodium a valuable medication in mitigating their impact. Despite its benefits, Montelukast sodium's use comes with potential adverse effects, including gastrointestinal discomfort and respiratory dysfunction.
What challenges does the Montelukast Sodium Industry face during its growth?
- Challenges associated with screening and diagnosis is a key challenge affecting the industry growth. The market holds significance in the context of noncommunicable diseases (NCDs), particularly respiratory diseases. Montelukast Sodium, a leukotriene inhibitor, is widely used for the treatment of asthma and allergic rhinitis in both children and adults. Asthma, a chronic respiratory condition, affects millions of Americans, leading to recurrent episodes of bronchospasm and respiratory dysfunction. This is available in various dosage forms, including tablets and oral solutions, making it convenient for patients. Allergic rhinitis, another common respiratory condition, is characterized by allergic coryza, itching, sneezing, and nasal congestion. It is also effective in managing symptoms of urticaria and exercise-induced asthma.
- However, it is crucial to note that it should not be used as a replacement for inhaled corticosteroids (ICS) for asthma management. The prevalence of respiratory diseases is influenced by various factors, including air pollution, smoking, and lifestyle changes. The pediatric population is particularly vulnerable to respiratory diseases due to their developing lungs. Montelukast Sodium is an essential medication for managing these conditions, and its availability in various dosage forms facilitates ease of use. Despite the benefits, there are potential adverse effects, such as gastrointestinal discomfort. Healthcare providers must consider these risks when prescribing Montelukast Sodium to patients.
Exclusive Customer Landscape
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Key Companies & Market Insights
Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the industry.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
- Apotex Inc.
- Aurobindo Pharma Ltd.
- Bio Techne Corp.
- Cayman Chemical Co
- Cipla Inc.
- Glenmark Pharmaceuticals Ltd.
- Hetero Healthcare Ltd.
- Hikma Pharmaceuticals Plc
- Jubilant Pharmova Ltd.
- Krosyl Pharmaceuticals Pvt. Ltd.
- Merck and Co. Inc.
- Morepen Laboratories Ltd.
- Novartis AG
- Simson Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Unichem Laboratories Ltd.
- Unimark Remedies Ltd.
- Viatris Inc.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Research Analyst Overview
Montelukast sodium is a leukotriene receptor antagonist used for the treatment of various chronic and acute respiratory conditions. This dosage form is available in both tablet and oral solution forms, providing flexibility for patients with different preferences and administration needs. This plays a significant role in managing noncommunicable diseases (NCDs), specifically those related to the respiratory system, in various populations. Chronic respiratory diseases, such as asthma, affect a substantial portion of the global population. According to recent estimates, asthma affects over 25 million children and 25 million adults in the United States alone. this is an essential medication for managing symptoms of asthma, allergic rhinitis, and other respiratory conditions.
Moreover, the prevalence of chronic conditions, including respiratory diseases, is a growing concern for healthcare providers and facilities. The role in managing these conditions is crucial, as it offers an alternative to inhaled corticosteroids (ICS) for some patients. In pediatric populations, it is often the preferred choice due to its ease of administration and fewer side effects compared to ICS. Pipeline analysis indicates that it continues to be an essential medication in the treatment of various respiratory conditions. The drug's versatility and effectiveness make it a valuable addition to healthcare infrastructure, especially in emergency departments and healthcare facilities treating patients with exercise-induced asthma and allergic rhinitis.
Furthermore, montelukast sodium's effectiveness is not limited to asthma and allergic rhinitis. It also plays a role in managing other respiratory maladies, such as bronchospasm, allergic coryza, and pneumonia. Furthermore, it is an effective treatment for urticaria and other allergic conditions. The market is experiencing growth as healthcare services increasingly adopt the medication to manage asthma and allergic rhinitis, enhancing patient outcomes and expanding. The usage extends beyond the pediatric population. The geriatric population also benefits from its use in managing chronic conditions and respiratory dysfunction. However, health complications associated with aging and drug consumption may necessitate adjustments in dosage and administration. The role in managing respiratory conditions is influenced by various factors, including lifestyle changes, air pollution, smoking, and fungal infections.
|
Montelukast Sodium Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
140 |
|
Base year |
2023 |
|
Historic period |
2018-2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
|
Market growth 2024-2028 |
USD 1.34 billion |
|
Market structure |
Fragmented |
|
YoY growth 2023-2024(%) |
4.2 |
|
Key countries |
US, China, Canada, Germany, and UK |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
What are the Key Data Covered in this Market Research and Growth Report?
- CAGR of the industry during the forecast period
- Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
- Precise estimation of the size of the market and its contribution of the industry in focus to the parent market
- Accurate predictions about upcoming growth and trends and changes in consumer behaviour
- Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
- Thorough analysis of the market's competitive landscape and detailed information about companies
- Comprehensive analysis of factors that will challenge the market growth of industry companies
We can help! Our analysts can customize this market research report to meet your requirements.